The effect of low-dose apalutamide in nonmetastatic castration-resistant prostate cancer is unknown. We report the observation of therapy being administered at 25% of the recommended dose in an 80-year-old patient. Despite treatment discontinuation during COVID lockdowns, he survived three years without evidence of metastasis. This case gently invites us to reflect on the possibility of low-dose apalutamide in the elderly.
Keywords: androgen receptor inhibitor; apalutamide; castration resistant prostate cancer; nonmetastatic castration-resistant prostate cancer; prostate cancer.
Copyright © 2024, Nguyen et al.